- Home
- CTO vs ARCT Comparison
CTO vs ARCT Comparison
Compare CTO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- ARCT
- Stock Information
- Founded
- CTO 1902
- ARCT 2013
- Country
- CTO United States
- ARCT United States
- Employees
- CTO N/A
- ARCT N/A
- Industry
- CTO Real Estate Investment Trusts
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- ARCT Health Care
- Exchange
- CTO Nasdaq
- ARCT Nasdaq
- Market Cap
- CTO 568.5M
- ARCT 298.3M
- IPO Year
- CTO N/A
- ARCT N/A
- Fundamental
- Price
- CTO $17.60
- ARCT $13.78
- Analyst Decision
- CTO Strong Buy
- ARCT Strong Buy
- Analyst Count
- CTO 3
- ARCT 8
- Target Price
- CTO $22.33
- ARCT $52.83
- AVG Volume (30 Days)
- CTO 399.4K
- ARCT 474.9K
- Earning Date
- CTO 07-29-2025
- ARCT 08-04-2025
- Dividend Yield
- CTO 8.63%
- ARCT N/A
- EPS Growth
- CTO N/A
- ARCT N/A
- EPS
- CTO N/A
- ARCT N/A
- Revenue
- CTO $132,203,000.00
- ARCT $143,680,000.00
- Revenue This Year
- CTO $20.11
- ARCT N/A
- Revenue Next Year
- CTO $8.51
- ARCT $34.79
- P/E Ratio
- CTO N/A
- ARCT N/A
- Revenue Growth
- CTO 17.48
- ARCT 15.38
- 52 Week Low
- CTO $16.12
- ARCT $8.04
- 52 Week High
- CTO $21.15
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- CTO 44.45
- ARCT 54.34
- Support Level
- CTO $17.11
- ARCT $13.10
- Resistance Level
- CTO $17.57
- ARCT $15.20
- Average True Range (ATR)
- CTO 0.37
- ARCT 1.02
- MACD
- CTO -0.01
- ARCT 0.07
- Stochastic Oscillator
- CTO 42.58
- ARCT 55.21
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.